Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfs48/45 Malaria Vaccine in Healthy UK Adults
NCT05400746Phase 1Terminated
- Sponsor
- University of Oxford
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Pfs48/45 in malaria (3 arms), sponsored by University of Oxford. Primary endpoints: Solicited Local Reactogenicity Signs and Symptoms, Solicited Systemic Reactogenicity Signs and Symptoms and 3 more. Started Nov 2022; status: terminated.
02
Drugs
Pfs48/45
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05400746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400746.